(Q34039419)

30 July 2017

Neurological and psychiatric adverse effects of antiretroviral drugs (English)

1 reference

30 July 2017

anti-retroviral agent

0 references

author name string

Michael S Abers

series ordinal

1

1 reference

PubMed ID

24362768

30 July 2017

Wayne X Shandera

series ordinal

2

1 reference

PubMed ID

24362768

30 July 2017

Joseph S Kass

series ordinal

3

1 reference

30 July 2017

1 February 2014

1 reference

30 July 2017

1 reference

30 July 2017

28

1 reference

30 July 2017

2

1 reference

30 July 2017

131-145

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-013-0132-4

30 July 2017

0 references

cites work

Zalcitabine and didanosine

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

HIV-associated sensory neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Plasma carnitine in HIV-associated neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Peripheral neuropathy and antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Leber hereditary optic neuropathy associated with antiretroviral therapy for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Late onset of Leber's hereditary optic neuropathy in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Optic neuropathy in a patient with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Highly active antiretroviral therapy: Does it Sound toxic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Noise-induced hearing loss in mice treated with antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Hearing loss and antiretroviral therapy in patients infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Mitochondrial myopathy caused by long-term zidovudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Azidothymidine neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Seizure after zidovudine overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Lethal neurotoxicity associated to azidothymidine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Coma during azidothymidine therapy for AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Manic syndrome associated with zidovudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Neuropsychiatric complications of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Dideoxyinosine in Children with Symptomatic Human Immunodeficiency Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Didanosine-induced retinopathy in adults can be reversible

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Neuromuscular manifestations of HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Miller Fisher variant of Guillain-Barré syndrome associated with lactic acidosis and stavudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

HIV-associated neuromuscular weakness syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Antiretroviral therapy-associated acute motor and sensory axonal neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Mitochondrial toxicity and HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Fatal exacerbation of peripheral neuropathy during lamivudine therapy: evidence for iatrogenic mitochondrial damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Exacerbation of peripheral neuropathy by lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Acute dystonia induced by lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Neuropsychiatric reaction induced by abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Antiretroviral therapy-induced psychosis: case report and brief review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Drug points: Neuropsychiatric complications of nevirapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Factors associated with efavirenz discontinuation in a large community-based sample of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Neurologic and psychiatric complications of antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz plasma concentrations and efficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Slow efavirenz metabolism genotype is common in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Clinical impact of patient population differences and genomic variation in efavirenz therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Successful efavirenz dose reduction guided by therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Myelomeningocele in a child with intrauterine exposure to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Teratogenicity risk of antiretroviral therapy in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Periconceptional exposure to efavirenz and neural tube defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Myelomeningocele in an infant with intrauterine exposure to efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efavirenz treatment and false-positive results in benzodiazepine screening tests.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Recurrence of post-traumatic stress disorder and antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Peripheral neuropathy in HIV: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Patient-reported nonadherence to HAART is related to protease inhibitor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Retinal pigment epitheliopathy, macular telangiectasis, and intraretinal crystal deposits in HIV-positive patients receiving ritonavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Photophobia in a patient with high indinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Ototoxicity may be associated with protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Central nervous system toxicity and amprenavir oral solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Protease inhibitor monotherapy and the CNS: peace of mind?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Increasing incidence of ischemic stroke in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

A report on the effect of commencing enfuvirtide on peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Enfuvirtide: a fusion inhibitor for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Exacerbation of depression associated with starting raltegravir: a report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Severe insomnia related to high concentrations of raltegravir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Long-term safety from the raltegravir clinical development program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Age and height predict neuropathy risk in patients with HIV prescribed stavudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Can we predict neuropathy risk before stavudine prescription in a resource-limited setting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0132-4

Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.

21 January 2018

1 reference

12 December 2020

Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity

1 reference

12 December 2020

Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS.

1 reference

12 December 2020

Does tenofovir influence efavirenz pharmacokinetics?

1 reference

12 December 2020

Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz

1 reference

12 December 2020

Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Uveitis following administration of the protease inhibitor indinavir to a patient with AIDS

1 reference

12 December 2020

Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006

1 reference

12 December 2020

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

1 reference

12 December 2020

Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy

1 reference

12 December 2020

Retinal toxicity associated with didanosine in HIV-infected adults

1 reference

12 December 2020

Rates and risk factors for adverse events associated with didanosine in the expanded access program

1 reference

12 December 2020

No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART

1 reference

12 December 2020

More on abacavir-induced neuropsychiatric reactions.

1 reference

12 December 2020

Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals

1 reference

12 December 2020

Non-Nucleoside Reverse Transcriptase Inhibitors Efavirenz and Nevirapine Inhibit Cytochrome C Oxidase in Mouse Brain Regions

1 reference

12 December 2020

Decreasing incidence of CNS AIDS defining events associated with antiretroviral therapy

1 reference

12 December 2020

Peripheral nerve function in persons with asymptomatic or minimally symptomatic HIV disease: absence of zidovudine neurotoxicity

1 reference

12 December 2020

A clinicopathologic report of the retinal lesions associated with didanosine

1 reference

12 December 2020

Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection

1 reference

12 December 2020

Zidovudine administration during pregnancy and mitochondrial disease in the offspring.

1 reference

12 December 2020

Retinal lesions in children treated with dideoxyinosine.

1 reference

12 December 2020

Manic syndrome associated with zidovudine

1 reference

12 December 2020

Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance.

1 reference

12 December 2020

Are adverse events of nevirapine and efavirenz related to plasma concentrations?

1 reference

12 December 2020

Leber's hereditary optic neuropathy in the setting of nucleoside analogue toxicity

1 reference

12 December 2020

Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.

1 reference

12 December 2020

Lactic acidosis associated with severe neuromuscular weakness and stavudine therapy

1 reference

12 December 2020

Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers

1 reference

12 December 2020

Cerebral MR imaging in uninfected children born to HIV-seropositive mothers and perinatally exposed to zidovudine.

1 reference

12 December 2020

Didanosine-induced mania in HIV infection.

1 reference

12 December 2020

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

1 reference

12 December 2020

Anterior uveitis and hypotony after intravenous cidofovir for the treatment of cytomegalovirus retinitis

1 reference

12 December 2020

Seizure associated with zidovudine

1 reference

12 December 2020

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

12 December 2020

Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.

1 reference

12 December 2020

Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment

1 reference

12 December 2020

Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection

1 reference

12 December 2020

Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group

1 reference

12 December 2020

Abacavir sulfate and mania in HIV

1 reference

12 December 2020

HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome

1 reference

12 December 2020

Zidovudine-related mania.

1 reference

12 December 2020

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

12 December 2020

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

12 December 2020

Effect of protease inhibitors on the sense of taste

1 reference

12 December 2020

The drugs 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy

1 reference

12 December 2020

Risk of early febrile seizure with perinatal exposure to nucleoside analogues

1 reference

12 December 2020

Deafness caused by didanosine

1 reference

12 December 2020

The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.

1 reference

12 December 2020

10.1007/S40263-013-0132-4

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

24362768